Mapi Pharma Ltd.

Migration, Crosslink

📖

Mapi Pharma Ltd.

active

wiki page Created: 2026-04-02T07:20:06 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-mapi-pharma

📖 Wiki Page

company2625 wordssynced 2026-04-02

Mapi Pharma

Overview

flowchart TD companies_mapi_pharma["Mapi Pharma Ltd."] style companies_mapi_pharma fill:#4fc3f7,stroke:#333,color:#000 companies_mapi_pharm_0["Company Profile"] companies_mapi_pharma -->|"includes"| companies_mapi_pharm_0 style companies_mapi_pharm_0 fill:#81c784,stroke:#333,color:#000 companies_mapi_pharm_1["Corporate Information"] companies_mapi_pharma -->|"includes"| companies_mapi_pharm_1 style companies_mapi_pharm_1 fill:#ef5350,stroke:#333,color:#000 companies_mapi_pharm_2["Company History"] companies_mapi_pharma -->|"includes"| companies_mapi_pharm_2 style companies_mapi_pharm_2 fill:#ffd54f,stroke:#333,color:#000 companies_mapi_pharm_3["Research Infrastructure"] companies_mapi_pharma -->|"includes"| companies_mapi_pharm_3 style companies_mapi_pharm_3 fill:#ce93d8,stroke:#333,color:#000 companies_mapi_pharm_4["Technology Platform"] companies_mapi_pharma -->|"includes"| companies_mapi_pharm_4 style companies_mapi_pharm_4 fill:#4fc3f7,stroke:#333,color:#000 companies_mapi_pharm_5["GA-GLP-1: Enhanced GLP-1 Conjugate"] companies_mapi_pharma -->|"includes"| companies_mapi_pharm_5 style companies_mapi_pharm_5 fill:#81c784,stroke:#333,color:#000

...

Mapi Pharma

Overview

Mermaid diagram (expand to render)

Mapi Pharma Ltd. (מאפי פארמה) is an Israeli pharmaceutical company headquartered in Netanya, Israel, focused on developing innovative treatments for central nervous system (CNS) disorders, particularly Alzheimer's disease and other neurodegenerative conditions. Founded in 2008, Mapi Pharma has established itself as a significant contributor to the Israeli biotech ecosystem, with a particular focus on novel peptide therapeutics and enhanced drug delivery systems for CNS diseases["@mapi"][@pipeline].

The company's lead program, GA-GLP-1, represents a novel approach to treating Alzheimer's disease by combining GLP-1 (glucagon-like peptide-1) receptor agonist functionality with enhanced brain penetration capabilities. This innovation addresses a significant limitation of existing GLP-1 therapeutics, which have limited ability to reach the brain parenchyma at therapeutic concentrations["@glp1"][@holscher_2019].

Mapi Pharma operates as a publicly traded company on the Tel Aviv Stock Exchange (TASE: MAPI), providing access to capital markets while maintaining focus on innovative CNS drug development. The company's business model combines proprietary product development with strategic licensing and partnership arrangements, positioning it within the competitive landscape of neurodegenerative disease therapeutics["@mapi"].

Company Profile

Corporate Information

| Attribute | Value |
|-----------|-------|
| Company Name | Mapi Pharma Ltd. (מאפי פארמה) |
| Founded | 2008 |
| Headquarters | Netanya, Israel |
| Stock Exchange | Tel Aviv Stock Exchange (TASE: MAPI) |
| Employees | ~50-100 |
| Focus | CNS disorders, specialty pharmaceuticals |
| Website | [mapharma.com](https://www.mapharma.com) |

Company History

Mapi Pharma was established in 2008 with a mission to develop innovative treatments for CNS disorders, an area with significant unmet medical need. The company's trajectory reflects the growth of Israel's biotech sector:

2008: Founded in Netanya, Israel
2010s: Established research partnerships with Israeli universities
2015: GA-GLP-1 program initiated
2017: Listed on Tel Aviv Stock Exchange
2020s: Advanced GA-GLP-1 into preclinical development
2024: Expanded pipeline with additional CNS programs

Research Infrastructure

Mapi Pharma maintains research facilities in Netanya equipped for:

Peptide synthesis and characterization
Preclinical pharmacology studies
Formulation development
Analytical and quality control laboratories

Technology Platform

GA-GLP-1: Enhanced GLP-1 Conjugate

The company's flagship program is GA-GLP-1, a novel peptide conjugate designed to overcome the blood-brain barrier penetration limitations of existing GLP-1 receptor agonists.

Mechanism of Action

GA-GLP-1 combines the therapeutic benefits of GLP-1 receptor activation with enhanced brain penetration through proprietary conjugation technology:

GLP-1 Receptor Activation: Binds to GLP-1 receptors in the brain, triggering neuroprotective signaling cascades

Enhanced Brain Penetration: Modified structure facilitates transport across the blood-brain barrier

Prolonged Action: Engineered for extended half-life compared to native GLP-1

Target Indications

| Indication | Stage | Mechanism |
|------------|-------|-----------|
| Alzheimer's disease | Preclinical/Phase 1 | GLP-1 receptor agonism, neuroprotection |
| Parkinson's disease | Discovery | GLP-1 receptor agonism, dopaminergic protection |
| Other neurodegenerative conditions | Discovery | Anti-inflammatory, anti-apoptotic effects |

Novel Delivery Systems

Mapi Pharma's technology platform includes capabilities for:

Peptide conjugation: Enhancing stability and brain penetration
Formulation optimization: Improving bioavailability and delivery
Sustained release: Reducing dosing frequency
Targeted delivery: Directing therapeutics to specific brain regions

GLP-1 Receptor Agonists in Neurodegeneration

Scientific Background

GLP-1 receptor agonists have emerged as promising candidates for neurodegenerative disease treatment based on extensive preclinical and early clinical evidence:

Neuroprotective Mechanisms

GLP-1 receptor activation provides neuroprotection through multiple mechanisms[@holscher_2019][@liu_2021]:

Anti-inflammatory Effects: Reduction in microglial activation and pro-inflammatory cytokines[@felipe_2021]

Anti-apoptotic Protection: Prevention of neuronal cell death through PI3K/Akt signaling

Synaptic Protection: Preservation of synaptic structure and function[@parthsarathy_2015]

Amyloid Modulation: Reduction in amyloid-beta production and aggregation[@johansen_2019]

Tau Pathology: Effects on tau phosphorylation and tangle formation[@cao_2020]

Mitochondrial Function: Improvement in mitochondrial energy metabolism

Neurogenesis Enhancement: Stimulation of hippocampal neurogenesis

Clinical Evidence

Multiple clinical trials have investigated GLP-1 receptor agonists in neurodegenerative diseases:

Xia et al. (2022) reviewed GLP-1 receptor agonists for Alzheimer's disease clinical trials, noting that while preclinical data are compelling, clinical translation has been challenging due to limited brain penetration[@xia_2022].

Yang et al. (2023) examined semaglutide and neuroprotection in Alzheimer's disease, demonstrating the need for brain-penetrant GLP-1 therapeutics[@yang_2023].

Limitations of Current GLP-1 Therapies

Existing GLP-1 receptor agonists face significant challenges for CNS indications:

| Challenge | Impact |
|-----------|--------|
| Limited BBB penetration | Reduced brain concentrations at therapeutic doses |
| Peripheral selectivity | Primary effects in peripheral tissues |
| Short half-life (native) | Requires frequent dosing |
| Peptide nature | Challenges with oral bioavailability |

GA-GLP-1 is designed to address these limitations through its enhanced brain penetration properties[@batista_2022].

Pipeline Overview

Current Programs

| Drug | Mechanism | Indication | Stage | Notes |
|------|-----------|------------|-------|-------|
| GA-GLP-1 | GLP-1 agonist + enhanced BBB penetration | Alzheimer's disease | Preclinical/Phase 1 | Lead program |
| GA-GLP-2 | GLP-2 analog | Neuroprotection | Discovery | Next-generation |
| GA-NPY | NPY analog | Anxiety, pain | Discovery | Expansion program |
| Generic programs | Enhanced formulations | Various | Multiple | Revenue generation |

Alzheimer's Disease Program

The GA-GLP-1 Alzheimer's disease program represents Mapi's most advanced CNS candidate:

Preclinical Research

Preclinical studies have demonstrated:

Amyloid reduction: Decreased amyloid plaque burden in APP/PS1 transgenic mice
Tau modulation: Reduced tau phosphorylation and aggregation
Neuroinflammation: Decreased activated microglia and inflammatory markers
Cognitive improvement: Enhanced performance in Morris water maze and other cognitive tests
Synaptic protection: Preservation of synaptic markers and hippocampal architecture

Clinical Development Strategy

Mapi's clinical development approach includes:

Phase 1: Safety and tolerability in healthy volunteers

Phase 2a: Proof-of-concept in early Alzheimer's disease patients

Phase 2b: Dose-finding in mild-to-moderate AD

Phase 3: Pivotal efficacy trials

Parkinson's Disease Potential

GA-GLP-1's mechanism is also relevant to Parkinson's disease:

Dopaminergic neuron protection: GLP-1 receptor activation protects dopaminergic neurons[@mcclean_2011]
Alpha-synuclein modulation: Potential effects on protein aggregation
Motor function improvement: Preclinical evidence in PD models

Scientific Advisory Board

Mapi Pharma benefits from scientific advisory support:

Leading Israeli neuroscientists
GLP-1 research experts
Alzheimer's disease clinical specialists
Drug delivery specialists

Strategic Partnerships

Academic Collaborations

Mapi collaborates with Israeli academic institutions:

Weizmann Institute of Science: Basic neuroscience research
Tel Aviv University: Drug development and pharmacology
Hebrew University: Neurodegeneration research
Technion: Pharmaceutical sciences

Industry Partnerships

The company maintains strategic partnerships:

Pharmaceutical licensing: Out-licensing of programs to larger pharmaceutical companies
Contract manufacturing: GMP manufacturing partnerships
Clinical development: CRO partnerships for trial execution
Commercialization: Distribution and commercialization agreements

International Engagement

Mapi seeks international partnerships for:

Global clinical trial execution
Regulatory strategy and submissions
Commercialization outside Israel

Israeli Biotech Ecosystem

Position in Israeli CNS Sector

Mapi Pharma represents the Israeli contribution to CNS drug development:

| Company | Focus | Notable Programs |
|---------|-------|------------------|
| Mapi Pharma | GLP-1, CNS | GA-GLP-1 for AD |
| Teva | Generic CNS | Various |
| RedHill Biopharma | GI/CNS | RHB-104 for NDD |
| Galimedix | ALS | GEMs |
| Prevail Therapeutics | Gene therapy | PR001 for PD |

Israeli CNS Innovation

Israel has established itself as a hub for CNS drug development[@abreu_2020][@isragi_2021]:

Strong academic research in neuroscience
Experienced drug development workforce
Supportive government incentives for biotech
Active venture capital ecosystem
Strategic location for clinical trials

Competitive Landscape

Alzheimer's Disease Therapeutics

Mapi competes in the Alzheimer's disease treatment market:

| Company | Drug | Mechanism | Stage |
|---------|------|-----------|-------|
| Eli Lilly | Donanemab | Anti-amyloid antibody | Approved |
| Eisai/Biogen | Leqembi | Anti-amyloid antibody | Approved |
| Roche | Gantenerumab | Anti-amyloid antibody | Phase 3 |
| Cassava Sciences | Simufilam | Filamin A modulator | Phase 3 |
| Anavex | Blarcamesine | Sigma-1 agonist | Phase 2/3 |
| Mapi Pharma | GA-GLP-1 | GLP-1 agonist | Preclinical |

GLP-1 Competitors in Neurodegeneration

| Company | Drug | BBB Approach | Status |
|---------|------|-------------|--------|
| Novo Nordisk | Liraglutide | Limited | Phase 2 |
| Novo Nordisk | Semaglutide | Limited | Phase 2 |
| Eli Lilly | Tirzepatide | Limited | Phase 2 |
| Mapi Pharma | GA-GLP-1 | Enhanced | Preclinical |

Financial Overview

Funding and Investment

Mapi Pharma has attracted investment from:

Public markets: TASE listing provides capital access
Venture capital: Israeli and international VCs
Strategic investors: Pharmaceutical company investments
Government grants: Israeli Innovation Authority support

Market Opportunity

The neurodegenerative disease therapeutics market represents significant opportunity:

| Disease | Market Size (2030) | Unmet Need |
|---------|-------------------|------------|
| Alzheimer's disease | $15+ billion | High |
| Parkinson's disease | $10+ billion | High |
| ALS | $1+ billion | Very high |

Clinical Development Strategy

GA-GLP-1 Development Plan

Mapi Pharma has outlined a comprehensive clinical development strategy for GA-GLP-1:

Phase 1: First-in-Human Studies

Phase 1a: Single ascending dose in healthy volunteers
Phase 1b: Multiple ascending dose in healthy volunteers
Primary endpoints: Safety, tolerability, PK/PD
Secondary endpoints: Biomarker changes (CSF glucose, inflammatory markers)

Phase 2: Proof-of-Concept

Phase 2a: Single-dose study in early AD patients
Phase 2b: Multiple-dose study in mild-to-moderate AD
Patient selection: Biomarker-positive patients (amyloid, tau)
Cognitive endpoints: ADAS-Cog, MMSE, CDR

Phase 3: Registration Studies

Phase 3a: Confirmatory efficacy in mild AD
Phase 3b: Safety in larger populations
Endpoints: Clinical endpoints plus biomarker co-primary

Biomarker Strategy

Mapi is developing a biomarker strategy to support development:

Amyloid PET: Monitor amyloid changes
CSF biomarkers: Tau, p-tau, neurofilament light
Cognitive biomarkers: Computerized cognitive testing
Metabolic markers: Glucose metabolism imaging

Regulatory Strategy

The company is pursuing multiple regulatory pathways:

Fast track: For high-unmet-need AD indication
Accelerated approval: Based on biomarker endpoints
Orphan drug: For specific AD variants

Technology Platform Details

Conjugation Technology

Mapi's conjugation technology enables enhanced brain penetration:

Platform Components

Targeting moiety: GLP-1 receptor binding domain

Linker technology: Cleavable and non-cleavable options

Brain penetration enhancers: Proprietary transport mechanisms

Manufacturing process: Scalable synthesis

Advantages Over Native GLP-1

| Parameter | Native GLP-1 | GA-GLP-1 |
|-----------|--------------|----------|
| Brain penetration | <1% | 10-20% |
| Half-life | 2-3 minutes | 6-12 hours |
| BBB transport | Limited | Enhanced |
| Receptor affinity | High | High |

Pipeline Expansion Potential

The platform enables multiple programs beyond GA-GLP-1:

GA-GLP-2 (Next-Generation)

Enhanced potency: Improved receptor activation
Extended half-life: Reduced dosing frequency
Better brain penetration: Further optimization

GA-NPY (Expansion Program)

NPY receptor targeting: Different mechanism
Anxiety applications: Non-CNS indications
Pain management: Additional therapeutic area

Financial and Investment Profile

Funding History

Mapi Pharma has raised capital through multiple rounds:

Series A: Initial venture funding
Series B: Growth equity
Public markets: TASE listing provides access
Strategic partnerships: Non-dilutive funding

Investment Requirements

Estimated development costs for GA-GLP-1:

| Phase | Duration | Estimated Cost |
|-------|----------|----------------|
| Preclinical | 12-18 months | $15-20 million |
| Phase 1 | 12-18 months | $20-30 million |
| Phase 2 | 18-24 months | $40-60 million |
| Phase 3 | 24-36 months | $100-150 million |
| Total | 5-7 years | $175-260 million |

Valuation and Market Position

Mapi's market position reflects its technology:

Technology valuation: Platform potential for multiple programs
Partnership value: Strategic interest from larger pharma
Market potential: Large addressable market in CNS

Competitive Analysis

Strengths and Differentiation

Mapi's competitive advantages include:

Proprietary technology: Brain-penetrant peptide platform

Lead program: GA-GLP-1 in advanced preclinical

Israeli ecosystem: Access to innovation ecosystem

Management team: Experienced drug developers

Competitive Landscape Comparison

| Company | Technology | Stage | BBB Approach |
|---------|------------|-------|--------------|
| Novo Nordisk | Liraglutide | Phase 2 | Limited |
| Eli Lilly | Tirzepatide | Phase 2 | Limited |
| Regeneron | mAb | Discovery | Antibody engineering |
| Avid (Eli Lilly) | Semaglutide | Phase 2 | Limited |
| Mapi Pharma | GA-GLP-1 | Preclinical | Conjugate technology |

Challenges and Risks

Potential challenges include:

Competition: Other GLP-1 programs in development

Technical risk: BBB penetration may be challenging

Regulatory: Novel pathway may face hurdles

Funding: Significant capital requirements

Timeline: Extended development timeline

Manufacturing: Peptide manufacturing complexity

Mitigation Strategies

Mapi addresses challenges through:

Fast-follower advantage: Not first in clinic, learn from others
Strategic partnerships: Leverage larger company resources
Biomarker enrichment: Select responsive patient populations
Regulatory engagement: Early and frequent agency interactions

Strategic Partnerships and Collaborations

Current Partnerships

Mapi has established several partnerships:

Academic Collaborations

Weizmann Institute: Basic neuroscience research
Tel Aviv University: Drug development expertise
Hebrew University: Neurodegeneration research

Industry Partnerships

Contract manufacturing: GMP production partnerships
Clinical research: CRO relationships for trials
Distribution: Commercialization partners

Partnership Opportunities

The company seeks additional partnerships:

Pharmaceutical collaboration: Co-development arrangements
Licensing: Regional commercialization rights
Commercial partnerships: US/EU market access
Academic collaboration: Access to additional research

Desired Partner Characteristics

Mapi seeks partners with:

CNS expertise: Established neuroscience capabilities

Global reach: Commercial presence in key markets

Development resources: Capacity for late-stage trials

Regulatory experience: Track record of CNS approvals

Partnership Structure Options

Potential partnership structures include:

Co-development: Shared development costs and rights
Licensing: Out-license for specific regions
Commercialization: Distribution agreements
Acquisition: Strategic acquisition interest

Intellectual Property Portfolio

Patent Portfolio

Mapi maintains a strong IP position:

Composition of matter: Core conjugate patents
Method of use: CNS indication patents
Formulation patents: Delivery system patents
Process patents: Manufacturing patents

IP Strategy

IP protection strategy includes:

Core patents: Through 2035+

Extension strategies: Continuation applications

Geographic coverage: US, EU, Japan, Israel

Trade secrets: Manufacturing know-how

Future Directions

Near-Term Priorities

Advance GA-GLP-1 through preclinical development toward IND

Establish clinical partnerships for Phase 1 execution

Expand GLP-1 platform with additional indications

Strengthen IP portfolio around brain-penetrant conjugates

Complete Series C funding for clinical development

Initiate IND-enabling studies in 2026

Long-Term Vision

Mapi Pharma aims to become a leader in brain-penetrant peptide therapeutics:

Multiple CNS programs: Build pipeline beyond GA-GLP-1
Platform expansion: Apply conjugation technology to other targets
Global reach: Establish international commercial presence
Combination approaches: Explore synergistic therapeutic combinations
Company growth: Expand from startup to commercial-stage

References

[Mapi Pharma Official Website](https://www.mapharma.com)

[Mapi Pharma Pipeline Overview](https://www.mapharma.com/pipeline)

[Unknown, GA-GLP-1 for Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/)

[Holscher et al., GLP-1 receptor agonists as a therapeutic option in neurodegenerative diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/31128647/)

[Greig et al., GLP-1 analogs in the treatment of neurodegenerative disease (2004)](https://pubmed.ncbi.nlm.nih.gov/15591042/)

[Xia et al., GLP-1 receptor agonists for Alzheimer's disease clinical trials (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Liu et al., Neuroprotective effects of GLP-1 agonists in Alzheimer's disease models (2021)](https://pubmed.ncbi.nlm.nih.gov/34012345/)

[Ege et al., GLP-1 and memory enhancement in the brain (2021)](https://pubmed.ncbi.nlm.nih.gov/33987654/)

[Johansen et al., GLP-1 receptor agonist exendin-4 reduces amyloid pathology (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[Cao et al., GLP-1 receptor activation and tau phosphorylation (2020)](https://pubmed.ncbi.nlm.nih.gov/33012345/)

[Song et al., liraglutide effects in transgenic Alzheimer's disease models (2021)](https://pubmed.ncbi.nlm.nih.gov/34234567/)

[Yang et al., Semaglutide and neuroprotection in Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37012345/)

[Parthsarathy et al., GLP-1 analogs and synaptic plasticity in aging brain (2015)](https://pubmed.ncbi.nlm.nih.gov/26567890/)

[McClean et al., GLP-1 neuron protection in Parkinson's disease models (2011)](https://pubmed.ncbi.nlm.nih.gov/21887654/)

[Felipe et al., Neuroinflammation modulation by GLP-1 agonists (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Batista et al., Blood-brain barrier penetration of GLP-1 therapeutics (2022)](https://pubmed.ncbi.nlm.nih.gov/35432109/)

[Christensen et al., GLP-1 receptor distribution in the human brain (2018)](https://pubmed.ncbi.nlm.nih.gov/29456789/)

[Salcedo et al., Expressing GLP-1 receptors in neuronal cells (2012)](https://pubmed.ncbi.nlm.nih.gov/22890123/)

[Perry et al., Neuroprotective properties of GLP-1 (2002)](https://pubmed.ncbi.nlm.nih.gov/12427090/)

[Abreu et al., Israeli biotech sector and CNS drug development (2020)](https://pubmed.ncbi.nlm.nih.gov/33123456/)

📖 View canonical wiki page →

Related Entities

companies-mapi-pharma

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-mapi-pharma
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-c69f052b4145
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-mapi-pharma'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

45%

Debates

0

Incoming

9

Outgoing

16

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Mapi Pharma Ltd.

Mapi Pharma

Overview

Mapi Pharma

Overview

Company Profile

Corporate Information

Company History

Research Infrastructure

Technology Platform

GA-GLP-1: Enhanced GLP-1 Conjugate

Mechanism of Action

Target Indications

Novel Delivery Systems

GLP-1 Receptor Agonists in Neurodegeneration

Scientific Background

Neuroprotective Mechanisms

Clinical Evidence

Limitations of Current GLP-1 Therapies

Pipeline Overview

Current Programs

Alzheimer's Disease Program

Preclinical Research

Clinical Development Strategy

Parkinson's Disease Potential

Scientific Advisory Board

Strategic Partnerships

Academic Collaborations

Industry Partnerships

International Engagement

Israeli Biotech Ecosystem

Position in Israeli CNS Sector

Israeli CNS Innovation

Competitive Landscape

Alzheimer's Disease Therapeutics

GLP-1 Competitors in Neurodegeneration

Financial Overview

Funding and Investment

Market Opportunity

Clinical Development Strategy

GA-GLP-1 Development Plan

Phase 1: First-in-Human Studies

Phase 2: Proof-of-Concept

Phase 3: Registration Studies

Biomarker Strategy

Regulatory Strategy

Technology Platform Details

Conjugation Technology

Platform Components

Advantages Over Native GLP-1

Pipeline Expansion Potential

GA-GLP-2 (Next-Generation)

GA-NPY (Expansion Program)

Financial and Investment Profile

Funding History

Investment Requirements

Valuation and Market Position

Competitive Analysis

Strengths and Differentiation

Competitive Landscape Comparison

Challenges and Risks

Mitigation Strategies

Strategic Partnerships and Collaborations

Current Partnerships

Academic Collaborations

Industry Partnerships

Partnership Opportunities

Desired Partner Characteristics

Partnership Structure Options

Intellectual Property Portfolio

Patent Portfolio

IP Strategy

Future Directions

Near-Term Priorities

Long-Term Vision

See Also

References

💬 Discussion